Lucia Gilling, MD
Endocrinology, Diabetes & Metabolism · Wesley Chapel, FLNPI 1174517247
Payments from drug & device makers
Across 234 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$855
- Mannkind Corporation$601
- Lilly USA, LLC$575
- Amgen$286
- Novo Nordisk$238
- AstraZeneca$209
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,47496%
- Education$1102%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 41 | $855 |
| Mannkind Corporation | 61 | $601 |
| Lilly USA, LLC | 12 | $575 |
| Amgen | 10 | $286 |
| Novo Nordisk | 21 | $238 |
| AstraZeneca | 11 | $209 |
| IBSA Pharma Inc. | 6 | $202 |
| Boehringer Ingelheim | 8 | $197 |
| Merck | 10 | $186 |
| Bayer | 3 | $169 |
| Abbott | 9 | $159 |
| Dexcom, Inc. | 7 | $141 |
| Medtronic(2 entities) | 7 | $129 |
| Amryt Pharma Holdings Ltd | 1 | $122 |
| Intuity Medical Inc | 1 | $103 |
| Insulet Corporation | 4 | $90 |
| Amneal Pharmaceuticals LLC | 4 | $57 |
| Radius Health, Inc. | 3 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $53 |
| AbbVie | 2 | $32 |
| Sequel Med Tech, LLC | 2 | $30 |
| BETA Bionics, Inc. | 2 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Valeritas, Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,644 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $251,381 |
| MounjaroTirzepatide | 81 | $149,222 |
| RybelsusSemaglutide | 81 | $142,597 |
| JardianceEmpagliflozin | 75 | $103,603 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $71,702 |
| JanuviaSitagliptin Phosphate | 50 | $55,312 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $46,199 |
| FarxigaDapagliflozin Propanediol | 36 | $41,339 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $40,669 |
| TrulicityDulaglutide | 29 | $40,273 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $33,981 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $28,920 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $28,773 |
| AfrezzaInsulin Regular, Human | 16 | $27,268 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $26,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $238 | $400,848278 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $575 | $197,593133 claims |
| Boehringer IngelheimJardiance, Tradjenta | $197 | $123,73790 claims |
| MerckJanuvia, Janumet Xr | $186 | $81,61869 claims |
| AstraZenecaFarxiga | $209 | $41,33936 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $855 | $28,77326 claims |
| Mannkind CorporationAfrezza | $601 | $27,26816 claims |
| AbbVieSynthroid, Armour Thyroid | $32 | $17,681186 claims |
| Johnson & JohnsonInvokana | $16 | $17,03417 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $57 | $3,603424 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $21 | $1,41420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Wesley Chapel
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.